Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135260 | 0.88 | HDAC1 (0.37) | IDO1SIGMAR1CYP3A4TMEM97MAPT | |
| SCHEMBL2151042 | 0.88 | SIGMAR1 (0.48) | L3MBTL1IDO1SIGMAR1CYP3A4TMEM97 | |
| SCHEMBL2779187 | 0.85 | SIGMAR1 (0.45) | IDO1SIGMAR1CYP3A4TMEM97CTSS | |
| SCHEMBL2164881 | 0.84 | NR1H4 (0.45) | L3MBTL1IDO1SIGMAR1CYP3A4TMEM97 | |
| SCHEMBL2818137 | 0.83 | L3MBTL1 (0.46) | L3MBTL1IDO1PPARAMAPTCTSS | |
| SCHEMBL2168456 | 0.81 | NR1H4 (0.44) | L3MBTL1IDO1SIGMAR1TMEM97CTSS | |
| SCHEMBL2164206 | 0.79 | SIGMAR1 (0.44) | IDO1SIGMAR1TMEM97CTSSNR1H4 | |
| SCHEMBL2818140 | 0.78 | L3MBTL1 (0.50) | L3MBTL1PPARAPPARGMAPTCTSS | |
| SCHEMBL2176308 | 0.77 | L3MBTL1 (0.50) | L3MBTL1IDO1PPARAMAPTCTSS | |
| SCHEMBL30958382 | 0.77 | L3MBTL1 (0.60) | L3MBTL1IDO1PPARACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | L3MBTL1 4107/4885IDO1 3948/4885PPARA 607/4885 |
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | L3MBTL1 4107/4885IDO1 3948/4885PPARA 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.